Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ST. JUDE MEDICAL TAPS LILLY EXEC MATRICARIA FOR PRESIDENT/CEO

This article was originally published in The Gray Sheet

Executive Summary

ST. JUDE MEDICAL TAPS LILLY EXEC MATRICARIA FOR PRESIDENT/CEO; the firm announced on March 17 that Lilly executive Ronald Matricaria will become the firm's president and CEO April 12. With the appointment of Matricaria, St. Jude is gaining a manager with experience in a wide range of medical device businesses to oversee the heart valve firm's diversification effort. Matricaria, who also has been named to St. Jude's board of directors, replaces Lawrence Lehmkuhl, who is moving up to chairman. Current Chairman William Hendrickson was named to the newly created position of Chairman Emeritus. A 23-year Lilly veteran, Matricaria joined the company in 1970 and held several sales, marketing and personnel posts until June 1984, when he was named president and CEO of the Cardiac Pacemakers, Inc. subsidiary. In January 1988, he moved to president of Lilly's diagnostics systems division and in February 1990, he added responsibilities in the medical instrument systems division. When the two divisions were merged in October 1990 to become the medical device and diagnostics division, Matricaria was named president of the business. Matricaria served in the position for nine months before becoming president of Lilly's international operations. In January of this year, he assumed the posts of executive vice president of Lilly's pharmaceutical division and president of its North American operations. The leader in the mechanical heart valve market, St. Jude has been slowly diversifying beyond its core U.S. heart valve business with the expansion of its cardiac assist and international marketing divisions. Matricaria is likely to accelerate the diversification effort. Hendrickson commented that "Matricaria is a highly talented general manager with the necessary skills and experience to build on the strength of our core business and make St. Jude Medical a more diversified medical products company." Matricaria said that he is "looking forward to making a substantial contribution to St. Jude Medical's evolution into a major diversified medical products company." Lehmkuhl became St. Jude's president and CEO in 1985, following 18 years with American Hospital Supply Corporation. During his tenure, St. Jude's annual sales have grown from $26 mil. to $240 mil. in fiscal 1992. Hendrickson was employed by American Home Products Corporation from 1961 to 1980 and served as vice president of the company from 1969 until his retirement in 1980. He became a member of St. Jude's board of directors in 1980 and was named chairman in October 1981.

You may also be interested in...



EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions

The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.

EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging

The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.

Stay Or Exit? Global Health Players Ponder New China Trajectory

It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel